Can Novo Nordisk bounce back?
Shares in Novo Nordisk fell as much as 15 per cent after the US Food and Drug Administration withheld approval for its new insulin treatment pending further tests. With a quick approval previously priced into its stock, the decision came as a shock to the company. Lex's Julia Grindell and Vincent Boland consider whether the group's shares are now fairly priced, and the impact of the decision on this year's earnings.
Produced by Nalini Sivathasan. Filmed by James MacDonald.